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ABSTRACT Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity. Relevant
mouse models are powerful for untangling this problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit
high levels of genomic instability leading to mammary tumors that have tumor gene expression profiles closely resembling mature
human mammary luminal cell signatures. We genomically characterized mammary adenocarcinomas from these mice to identify
cancer-causing genomic events that overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy
number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in nearly all cases. These overlap with
human CNAs including NF1, which is deleted or mutated in 27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS
hyperactivation and increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 loss can drive breast
cancer. This should be informative for treatment of the significant fraction of patients whose tumors bear NF1 mutations.
TWIN and family studies indicate that only 25% ofbreast cancer cases have a heritable basis, and thus the
majority (75%) appear to be “sporadic” (Lichtenstein et al.
2000). Hence, much effort is now being placed on genomic
analysis of breast and other cancers, focusing on cancer
genome alterations in addition to inherited genetic varia-
tion. Comprehensive large-scale studies have been, and
are being conducted in an attempt to identify genes and
pathways that are commonly altered in various cancers,
and which may thus represent cancer “drivers” with causa-
tive roles. However, the prevalence of passenger mutations,
genetic heterogeneity, and the diversity of tumor etiologies
and subtypes complicates unequivocal identification of
drivers. Therefore, validation of cancer drivers—especially
novel ones—requires orthogonal lines of evidence and exper-
imental confirmation. In this regard, mouse models can play
an important role.
One putative cancer driver that has emerged is NF1
(Neurofibromin 1). Best known for causing the autosomal
dominant genetic disorder neurofibromatosis type 1, cancer
genome resequencing studies are finding evidence that NF1
is mutated (either by deletion or intragenic mutation) at
significant rates in different cancers. NF1 is a negative reg-
ulator of the RAS oncogene. It stimulates the GTPase activity
of RAS (and thus is a “RasGAP”), pushing it to the inactive
GDP-bound state. NF1 is the third most prevalently mutated
or deleted gene in glioblastoma multiforme (GBM) (The
Cancer Genome Atlas Research Network 2008), one of the
most significantly mutated genes in lung adenocarcinoma
(Ding et al. 2008), and the fourth most (intragenically) mu-
tated gene in ovarian carcinoma (The Cancer Genome Atlas
Research Network 2011). Although NF1 alteration has not
yet been implicated as a significant breast cancer driver, loss
of heterozygosity (LOH) of NF1 has been noted in occasional
cases (Guran and Safali 2005; Lee et al. 2010), as have in-
tragenic mutations (Stephens et al. 2012). Women with neu-
rofibromatosis type 1 (NF-1; a result of inheriting a mutant
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NF1 allele), have an increased risk of, or association with,
breast cancer (Sharif et al. 2007; Salemis et al. 2010). Ad-
ditionally, siRNA-mediated NF1 knockdown in epithelial-like
breast cancer cells induced the expression of epithelial-to-
mesenchymal transition-related transcription factors (Arima
et al. 2009). However, it remains uncertain whether the NF1
mutations in these cases actually contribute to cancer etiology
or maintenance.
Here, we took a comparative oncogenomic approach for
breast cancer driver identification, exploiting the highly
relevant mouse model C3H-Mcm4Chaos3/Chaos3. These mice
bear a point mutation in the minichromosome maintenance
4 (Mcm4) gene that destabilizes the essential MCM2-7 rep-
licative helicase. The resulting genomic instability (GIN)
causes .80% of nulliparous females to develop mammary
adenocarcinomas exclusively (Shima et al. 2007). The con-
trolled genetic background and singular tumor etiology allows
identification of recurrent mutational events likely to be in-
volved in driving tumorigenesis. Strikingly, nearly all mammary
tumors contained Nf1 deletions. Furthermore, examination of
The Cancer Genome Atlas (TCGA) data revealed that over
a quarter of all human breast carcinomas are missing at least
one copy of NF1. These findings indicate a potentially prom-




Chaos3 mammary tumors originated in mice congenic in
C3HeB/FeJ except 16898. Chaos3 tumor 16898 and other
Chaos3 tumors arose in a mixed C57BL/6J and C3HeB/FeJ
background. MMTV-neu and PyVT mammary tumors occurred
in the FvB background.
Microarray expression profiling
RNA was hybridized to custom murine Agilent microarrays
and normalized as described (Herschkowitz et al. 2007,
2012). Data were deposited into the Gene Expression Omni-
bus (accession no. GSE36240). Chaos3 tumors were clustered
in relation to other mouse models using an unsupervised
analysis, and differentiation score was calculated as de-
scribed (Herschkowitz et al. 2007; Prat et al. 2010). Signif-
icance analysis of microarray (SAM) results were used to
define a Chaos3 gene signature (upregulated, FDR 0%),
which was analyzed using the UNC337 human tumor data
set (Prat et al. 2010). Genes significantly differentially ex-
pressed between Chaos3 tumors and those of other mouse
models are presented in Supporting Information, File S1.
Partial exome resequencing
A custom mouse 5-Mb Sequence Capture array (NimbleGen)
was used to enrich DNA corresponding to 1200 breast
cancer candidate gene exons (File S2), followed by Illumina
GAIIx sequencing. Candidate genes were selected and ranked
based on breast cancer specificity and frequency in primary
literature, existing cancer arrays, and cancer databases.
The sequence capture was performed as follows. Genomic
DNA libraries of 200-bp fragment size were constructed
for four Chaos3 mammary tumors and one inbred C3H WT
spleen following the standard protocol of Illumina (San
Diego). One microgram of tumor and control library DNA
was hybridized to the 385 K or 720 K capture array using an
X1 mixer on the NimbleGen Hybridization system (Roche-
NimbleGen) at 42 for 3 days. Arrays were washed; then
the captured molecules were eluted from the slides using a
NimbleGen Elution Station. Eluted molecules were vacuum
dried and amplified by ligation-mediated (LM)-PCR. Real-
time PCR of eight control amplicons was performed in the
precapture and postcapture library to estimate the target
fold enrichment, which varied from 30- to 744-fold.
The read data from each sample were aligned to the
mouse C57BL/6, NCBI Build 37 (mm9) reference sequence
using Novoalign (http://novocraft.com, v 2.05, academic ver-
sion). Default alignment settings were used, but nonuniquely
mapped reads or reads failing on alignment quality were
discarded (-r NONE -Q 9). The percentage of on-target reads
for mutant samples ranged from 34.5 to 62.9%, reflecting
a 230-fold average enrichment for the target breast cancer
candidate genes. Genome Analysis Toolkit (GATK) version
1.04413 was used sequentially for base quality recalibra-
tion, depth of coverage estimation, variant calling, and var-
iant evaluation (DePristo et al. 2011). Substitution variants
discovery and genotyping were performed with the GATK
Unified Genotyper across all samples simultaneously. Single
sample SNP calling was used to complement joint-sample
SNP calling. The raw SNP calls were filtered per GATK rec-
ommendations with standard hard filtering parameters or
variant quality score recalibration (DePristo et al. 2011).
Criterion required SNP loci to have $5· coverage, variant
frequency in $25% of reads, missing bases ,30%, no sig-
nificant strand bias, and not overlapping indels. Indels were
called with GATK IndelGenotyperV2 under both single sam-
ple and paired sample modes using C3H as the “normal”
tissue to identify novel indels against C3H. No novel indels
were identified in targeted coding regions. Known SNPs
between C3H and C57BL/6J were mined from the Mouse
Genome Database (http://www.informatics.jax.org/mgihome/
projects/overview.shtml#snp), dbSNP (Sherry et al. 2001),
and Sanger Mouse Genome Project (Keane et al. 2011)
(http://www.sanger.ac.uk/resources/mouse/genomes/). There
were 3,097 known C3H SNPs in seqcap target regions from
traditional Sanger sequencing. GATK joint estimation from
in-house data identified 2990 filtered SNPs, representing a
96.6% sensitivity. Known C3H SNPs were filtered out, and
novel SNPs were identified for annotation and validation.
Variation consequence was annotated with Ensembl Variation
API (http://www.ensembl.org/info/docs/api/variation/index.
html) and custom perl scripts. Binary Sequence Alignment/
Map (BAM), Blue Elephant Definition (BED), and Variant
Call Format (VCF) files were generated to visualize alignments
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and variations using the Integrative Genomics Viewer (IGV)
software (Robinson et al. 2011). Variants were manually
examined in IGV before proceeding to Sanger sequence val-
idation as follows. Variant positions were amplified in cor-
responding tumor samples and inbred C3H control genomic
DNA. Following Fast AP and Exo1 (Fermentas) treatment,
PCR products were Sanger sequenced and analyzed using
SeqMan. GeneCard, Ingenuity Pathway Tool, Biocarta, and
KEGG databases were used to annotate genes.
Array comparative genomic hybridization
Five micrograms of genomic DNA from tumor and reference
samples were labeled and hybridized to 3 · 720 K mouse
Nimblegen CGH whole genome tiling arrays. The arrays con-
sist of 50–75mer probes and a median spacing of 3.5 kb, with
a subset of probes concentrated on exons. Two reference
samples were used independently to ensure recurring CNAs
were not artifacts caused by the reference sample. The first
reference sample was collected from a C3HWT inbred mouse
and run with tumor samples 2044b, 12351, and 12353. The
second reference sample selected originated from a C3H
congenic Chaos3+/+ mouse and run as the reference for
the remaining samples. DNA labeling, hybridization, and
posthybridization processing were performed according to
the manufacturer’s protocol. Nimblegen software was used
to normalize test/reference ratios and perform background
correction. Copy number changes were identified and seg-
mented with Nimblegen CGH-segMNT algorithm using un-
averaged and 10· averaging windows. The significance
threshold was set at 6 0.15 log2 ratio and required a min-
imum of two consecutive probes to exhibit a change in order
to call a segment. Amplifications and deletions were visual-
ized using Nimblegen software and confirmed by manually
examining log2 ratios for regions of interest. In addition to
using Nimblegen software, the normalized log2 ratio data
were also analyzed using KCSmart software (Klijn et al.
2008) to identify significantly recurrent CNAs. The kernel
width was 1 Mb, and the resolution of the sample point
matrix was 5 Kb. Simple Bonferroni multiple testing cor-
rection P , = 0.025 was used as threshold for declaring
significant regions. Select genes within CNAs were validated
via qPCR. See File S3 for the primer list.
Human breast cancer data and CNA calls for comparison
with Chaos3 CNAs were taken from the publicly available
Cancer Genome Atlas portal (https://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp) 2010 update. The regions considered
to have undergone segmental deletions by the publicly avail-
able Cancer Genome Atlas analysis (“level 4” data set) are
those indicated in Figure 2B. The Memorial Sloan-Kettering
Cancer Center cBio portal provides a breakdown by mammary
tumor subtype for individual genes (http://www.cbioportal.
org/public-portal/index.do). According to the cBioPortal data
available as of May 2012, the genes between the NOS2
and NF1 interval (which were not classified as significantly
segmentally deleted in the limited level 4 data set men-
tioned above), are hemizygously deleted at rates similar to
NF1 itself. Critical regions within each Chaos3 CNAwere iden-
tified as the region with the greatest overlap across multiple
Chaos3 tumors.
Cell culture experiments
Primary Chaos3 tumor biopsies were homogenized, cultured,
treated with colcemid, and metaphase spreads were made
(Shima et al. 2007). Imaged chromosomes were counted
Figure 1 Chaos3 tumors model key human features. (A) Expression micro-
array dendrogram of Chaos3mammary tumors and 185 other mouse mam-
mary carcinomas and normal mammary tissue samples. The Chaos3 tumors
cluster together as a distinct group near luminal murine models: MYC,
PyMT, and Her2/Neu. Genes significantly differentially expressed between
Chaos3 tumors and those of other mouse models are presented in File S1.
(B) Boxplot of the Chaos3 gene signature in the UNC337 human breast
tumor data set. Chaos3 tumors have higher signature expression in human
luminal, HER2-enriched, and normal-like intrinsic subtypes. (C) Chaos3 dif-
ferentiation score (D score) in relationship with other genetically engineered
mouse models (GEMMs). The high D score shows that Chaos3 tumors
more closely resemble the expression signature of mature human luminal
cells relative to all other mouse models analyzed. (B and C) P-values reflect
statistical significance of ANOVAs. MaSC, mammary stem cell.
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using ImageJ. Tumor cell lines were treated with the MEK1
inhibitor PD98059 or MTOR inhibitor rapamycin (Chang et al.
2007; Leong et al. 2010). Cell proliferation was assessed via
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (Sigma) and values read on a 96-well ELISA
plate reader.
Active RAS pull-down and Western blotting
Levels of activated RAS were obtained using an active RAS
pull-down kit (Thermo Scientific). Rabbit anti-NF1 (Novus
Biologicals) was used at 2 mg/ml for Western analyses.
Results
Gene expression profiling reveals that the
Mcm4Chaos3/Chaos3 mouse is a highly
relevant luminal breast cancer model
Human breast tumors can be classified into subtypes using
gene expression signatures that are also conserved within
mouse models of mammary cancers (Perou et al. 2000;
Herschkowitz et al. 2007). Mcm4Chaos3/Chaos3 mammary
tumors (referred to as “Chaos3”) are histologically classified
as adenocarcinomas (Shima et al. 2007), and comparison with
the 185 mouse mammary tumor data set of Herschkowitz
et al. (2012) shows clustering near three luminal adenocarci-
noma mouse models (Figure 1A). Consistent with this, the
Chaos3 gene signature was most highly expressed in the hu-
man luminal A subtype, and was also high in HER2-enriched
and luminal B tumors (Figure 1B). Luminal breast tumors are
the most prevalent type in humans (Carey et al. 2006). SAM
revealed that Chaos3 tumors have a distinct gene expression
pattern from all other mouse models, including dramatic upre-
gulation ofMucl1, a diagnostic marker in human breast cancer
(Table S1) (Hube et al. 2004). Tumor differentiation score
(D score) analysis showed that Chaos3 tumors more closely
resemble mature human luminal cells than any mouse
model analyzed to date (Figure 1C). Together, these results
show that Chaos3mice are an excellent human breast cancer
model.
Evidence that Chaos3 mammary tumors are driven
by recurrent CNAs overlapping those common to human
breast cancers
Primary Chaos3 cells have increased stalled replication forks
that persist through metaphase, leading to chromosome
breaks and improper chromosomal segregation (Shima et al.
Figure 2 Recurrent CNAs in Chaos3 mammary tumors overlap with those in human breast cancer, including Nf1 deletion. (A) KCSmart analysis of
combined aCGH data from 12 Chaos3 tumors, (nine mammary and three nonmammary). The most significant amplification peaks (red) lie on Chrs 12
and 16, and deletions (green) on Chrs 4, 5, and 11. (B) Overlap of mouse (Mmu) Chaos3 recurrent deletions with human (Hs) breast tumor CNAs.
Human gene orders are shown. Thick red bars indicate the critical regions of mouse deletions, the subregions that, among all alterations in those
regions, are common across all or most Chaos3 tumors. Of Chaos3 tumors with CNAs in these regions, the percentage of those containing the critical
region is as follows: Chr 4 132 M = 86%; Chr 4 148 M = 71%; Chr 5 = 86%; Chr 11 = 86% (100% for Nf1, Ksr1, and Wsb1). The thick black bars to
the right of the gene symbols indicate corresponding recurrent segmental CNAs in human breast cancers (limited level 4 data set from TCGA). Note that
the Chr 11 deletions are single events in mice (asterisks on red part indicate these sequences are juxtaposed and contiguous in the mouse genome), and
it is possible that the interval between NOS2 and NF1 may also be deleted as single events in human breast cancers, since the intervening genes are
present in the hemizygous state in a high percentage of tumors according to extended TCGA data sets.
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2007; Kawabata et al. 2011a,b). Similar to human breast
tumors (Hanahan and Weinberg 2011), Chaos3 tumors had
high levels of aneuploidy and drastic variation in chro-
mosome number, even within the cells of a single tumor
(Figure S1). With such intratumor variation, we expect that
only early and/or highly selected mutations would be read-
ily detectable and highly recurrent across multiple cases.
To uncover mutations potentially driving carcinogenesis in
Chaos3 mice, we first performed partial exome resequencing
of mammary tumors. Surprisingly, we discovered few so-
matic point mutations in the targeted exonic regions and
calculated the mutation rate at 1.1 · 1027, or 0.25 muta-
tions/Mb, which is not above the background rate in other
genomic studies of breast cancer (Greenman et al. 2007;
Kan et al. 2010). The mutated genes are involved in diverse
functions or are simply large (i.e., Titin), and together they
do not implicate a commonly affected pathway underlying
carcinogenesis (Table S1). These results indicate that elevated
intragenic mutagenesis is not the primary mechanism driving
Chaos3 carcinogenesis, and that other initiators such as CNAs
may be responsible.
Saccharomyces cerevisiae containing the Chaos3 mutation
have elevated translocations as well as segmental amplifica-
tions and deletions (Li et al. 2009). To examine genomic
copy number changes, we performed array comparative
genomic hybridization (aCGH) on 12 Chaos3 tumors (nine
Chaos3 mammary and three nonmammary), and two MMTV-
Neu mammary tumors. Chaos3 nonmammary tumors can be
obtained by genetic perturbations or altering the strain back-
ground (Chuang et al. 2010; Kawabata et al. 2011b). Strik-
ingly, the Chaos3 tumors exhibited highly recurrent CNAs in
a small number of regions. Nearly all tumors had amplifica-
tions on chromosomes (Chr) 12 and 16 regardless of tumor
type (Figure 2A; Table 1). Deletions on Chrs 5 and 11 were
found in Chaos3 mammary tumors specifically, and there
was a small commonly deleted region on Chr 4 that was
shared by Chaos3 and MMTV-neu mammary tumors (Table 1).
We screened TCGA human breast cancer genomic data and
found commonly deleted regions overlapping the syntenic
regions of recurrent Chaos3 deletions (Figure 2B, Table S2,
and Table S3). Interestingly, the Chr 12 amplifications had
precise breakpoints (Table 1) that flank a region enriched in
immunoglobulin (Ig) gene fragments. While none of the six
recurrently amplified regions were unique to Chaos3 mam-
mary tumors, genes in these regions have roles in metastasis,
pluripotency, signal transduction, or are upregulated in cancer
(Table 2). The recurrently deleted regions contain several
genes that overlap with human breast cancer CNAs and/or
have potential or suggested roles in cancer: Ube4b (an ubiq-
uitin ligase that negatively regulates Trp53) (Wu et al.
2011), Kif1b (a potential haploinsufficient tumor suppressor)
(Munirajan et al. 2008), and Rad9 (deleted in three of the
nine tumors, it is involved in the Ataxia telangiectasia and
Rad3 related (ATR) DNA damage response pathway; muta-
tion or misregulation of this gene is associated with various
cancers, including breast) (Lieberman et al. 2011) (Table 2,
Table S2, and Table S3).
Nf1 is deleted in nearly all Chaos3 mammary tumors
and a high proportion of human breast cancers
Particularly striking to us is the set of Chaos3 deletions on
Chr 11 that overlaps with a recurring cluster of CNAs on
human Chr 17. All Chaos3 mammary tumors examined by
aCGH but none of the MMTV-Neu driven mammary tumors
or Chaos3 nonmammary tumors contained Chr 11 deletions
(Figure 3, A and B, Table 1, Table S2, and Table S3). The
small deletions have nested breakpoints that define a com-
monly deleted region, and all of which contained the tumor
suppressor Nf1 (Neurofibromin 1), Omg (oligodendrocyte
myelin glycoprotein; this gene lies within an intron of Nf1),
Wsb1 (WD repeat and SOCS box-containing protein 1), and
Ksr1 (kinase suppressor of RAS) (Figure 3B). Except for Nf1,
none have a plausible role as a mammary tumor suppressor.
Omg is expressed primarily in neural tissues and is required
for myelination in the central nervous system. Ksr1 pro-
motes oncogenic RAS and MAPK signaling in mice and
cells, so its deletion would be expected to actually inhibit
tumor growth (Lozano et al. 2003; Goettel et al. 2011).
WSB1 appears to participate in an E3 ubiquitin ligase com-
plex not known to be associated with cancers. The gene
Rab11fip4, which is deleted in many but not all of the Chaos3
mamary tumors, acts as a regulator of endocytic traffic but
Table 2 Cancer and immunity-related genes in Chaos3 mammary tumor CNAs
Amplified Deleted
Function Chr 16 Chr 12 Function Chr 4 Chr 5 Chr 11 Chr 10 Chr 19






















Cancer related Arid1a, Sfn* Sbno1 Minpp1*
The genes commonly altered specifically in mammary tumors are underlined, and those that additionally have CNAs in human breast cancers are marked with an asterisk. Ig/
abparts, Ig locus and antibody parts gene feature conserved between mice and humans.
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is expressed predominantly in retina and neural tissues,
with little or no detectable expression in mouse or human
mammary tissue (microarray data viewable at BioGPS.org
and GeneCards.org).
These data and information led us further to explore the
potential role of Nf1 as a driver of Chaos3mammary tumors.
We analyzed the DNA of the aCGH samples and additional
Chaos3 mammary tumors by qPCR. Overall, 59/60 contained
Nf1 deletions, with 51.6% appearing homozygous and 46.6%
heterozygous (Table 3 and Table S4). Nf1-deleted tumors
showed absence or severe reduction of mRNA and protein
(Figures 3C and 4A). NF1 negatively regulates RAS, which
Figure 3 Nf1 is deleted in Chaos3 mammary tumors. (A) Recurrent deletions detected by aCGH on Chr 11 at 79 Mb, specific to Chaos3 mammary
tumors. The broken red line indicates significant log2 ratios. Tumor 17883 is a mediastinal lymphoma/leukemic tumor, 16862 is a histiocytic sarcoma
in the uterus, 10658 is a bone tumor, and the other tumors are mammary. Mammary tumors 16168 and 12352 did not have significant detectable
deletion by aCGH, but did by qPCR (Table S4). (B, Top) aCGH results of two primary Chaos3 mammary tumors and one Chaos3 mammary tumor cell
line. Dots substantially above the log2 ratio line correspond to loci amplified in the tumor, and dots below are underrepresented. Arrows mark loci
commonly amplified in Chaos3 tumors regardless of tumor type, and asterisks mark commonly deleted loci segregating specifically with mammary
tumors. (Bottom) Expanded view of Chr 11 deletion. Red bars indicate aCGH or qPCR confirmed deletion in all nine Chaos3 mammary tumors
overlapping Nf1. (C) qRT–PCR analysis of Nf1 mRNA levels across the transcript in Chaos3 tumors. Percentage of expression is relative to an MMTV-
PyVT tumor as control, which does not have loss of Nf1. Error bars show standard error of the mean. Mammary tumor 15259 is heterozygously deleted
for Nf1, and the others are homozygously deleted. Residual signal may reflect biopsy contamination or tumor heterogeneity.
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controls proliferation, differentiation, cell adhesion, apo-
ptosis, and cell migration through the MAPK and PI3K sig-
nal transduction pathways (Figure 4B). RAS proteins are
often deregulated in cancers, leading to increased invasion
and metastasis and decreased apoptosis (Pylayeva-Gupta
et al. 2011).
Best known for causing neurofibromas in the autosomal
dominant genetic disorder neurofibromatosis type 1, women
with inherited NF1 deficiency also have an increased risk
of, or association with, breast cancer (Sharif et al. 2007;
Salemis et al. 2010). Though there are few reports implicat-
ing spontaneous Nf1 loss in breast tumorigenesis (Guran
and Safali 2005; Lee et al. 2010), upon screening TCGA
breast cancer data sets we found that 27.7% of human breast
tumors have NF1 deletions or mutations, most being hetero-
zygous (Figure 5A and File S4). Furthermore, .40% of basal
and HER2-enriched tumor subtypes have NF1 loss or muta-
tions (Figure 5A). Genomic NF1 deficiency in human breast
tumors significantly correlated with decreased expression lev-
els (P = 3.32 · 10213) (Figure 5B), both supporting the
deletion calls and that the deletions impact NF1 levels.
Chaos3 mammary tumors have hyperactivated RAS
NF1 is a negative regulator of the RAS signaling pathway
that stimulates the GTPase activity of RAS, pushing it to
the inactive state. NF1 is important for negatively regulating
the progrowth factor mTOR, which is stimulated by RAS
(Figure 4B). Tumor cells of patients with acute myelogenous
leukemia (AML) having NF1 deficiency demonstrate an el-
evated level of activated RAS and sensitivity to the mTOR
inhibitor rapamycin (Parkin et al. 2010). To assess the func-
tional impact of Nf1 deletion, we examined the level of ac-
tivated RAS and found it to be dramatically higher in Chaos3
mammary tumor cells deleted for Nf1 (Figure 4A). We
hypothesized that if the elevation of RAS signaling in
Nf1-deleted mammary tumor cells is important for their main-
tenance, then inhibition of downstream pathways would
compromise the growth of these cells. Chaos3 mammary
tumor cell lines were markedly sensitive to MAPK/MEK1
and/or mTOR inhibitors, PD98059 and rapamycin, respec-
tively (Figure 4C).
Discussion
Cancer genome resequencing studies are finding evidence
that NF1 is mutated (either by deletion or intragenic muta-
tion) at significant rates in different cancers. The two major
studies published by TCGA Research Network on glioblas-
toma multiforme and ovarian carcinoma both found that
NF1 and the PI3K/RAS pathway were mutated at signifi-
cantly elevated rates (The Cancer Genome Atlas Research
Network 2008, 2011). Though the TCGA Research Network
has yet to publish its breast cancer genome data, the corre-
lation between lower NF1 expression and copy number (as
called by their implementation of the GISTIC algorithm)
supports their calls of NF1 heterozygosity in the tumors
they examined. Canonically, tumor suppressors are thought
to require loss of both copies to have functional impact.
However, there is accumulating evidence that haploinsuffi-
ciency or reduced expression of tumor suppressor genes can
influence carcinogenesis (Berger et al. 2011). Indeed het-
erozygosity for Nf1 causes cancer-like cellular phenotypes
in astrocytes (Gutmann et al. 1999; Bajenaru et al. 2001;
Gutmann et al. 2001). We note that a recent cancer genome
study did not report a high frequency of NF1 CNAs (Curtis
et al. 2012). It is likely that the differences are related to
different analytical methods of CNA calling and they high-
light the need for follow-up analyses such as the qPCR we
performed on the mouse tumors.
The mechanistic basis behind frequent deletion of NF1/
Nf1 as opposed to intragenic mutation is an intriguing ques-
tion that could yield insight into etiology of cancers with
NF1 deletion. A combination of factors may contribute to
NF1 CNAs, including fragile sites in the vicinity (Figure S2),
a complex chromatin structure, and/or the gene’s large size.
Replication fork stalling near Nf1 has been noted at a 5-kb
Table 3 qPCR analysis of deletions in Chaos3 mammary tumors
DNAs
15259 12351L 12353A 12352 2044B 11929A 16168 16898 12115B WT
Chr 4 Kif1b 53.0 141.1 77.8 25.9 61.3 96.5
Pik3cd 55.8 134.6 89.9 29.2 55.4 103.3
Eno1 58.7 87.3 105.3 39.3 51.5 108.4
Rere 51.7 108.9 104.4 32.4 48.9 100.6
Chr 11 Slc46a1 82.2 36.7
Tnfaip1 92.9 71.4 79.3 65.0 83.4 59.8
Nlk 103.6 63.5 105.4 67.5 116.0 50.5
Nf1 (59) 17.4 35.5 25.5 12.7 63.7 16.7 9.2 9.6 31.2 107.3
Omg (Nf1 39) 52.9 12.0 16.7 0.7 48.0 16.3 75.1 38.7 109.4
Rab11fip4 49.8 65.9
qPCR values are presented in percentage of genomic DNA compared to C3H wild type. Boldfaced data indicate heterozygous or homozygous deletion (,80% control
signal). Cancer-related genes, deleted at high frequency in mammary tumors specifically, are underlined. Nf1 deletion was validated at the 59 and 39 ends of the gene (Omg
lies within an intron near the 39 end of Nf1). Note that copy number differences between Nf1 59 and 39 are observed in some tumors, indicating a breakpoint within the
Nf1 gene. Deletion calls were made as follows: Heterozygous = 15–80%; homozygous = ,15%; if either Nf1 or Omg were ,15%, the tumor sample was called as
homozygously deleted (see text for overall summary; data for tumors not examined by aCGH are not shown here) because full Nf1 transcripts cannot be made. Nucleotide
positions are from the mm9 mouse assembly. Sample 2044B is a tumor-derived cell line. WT, wild type.
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isochore transition zone conserved between human and
mouse, separating early and late replicating chromatin
(Schmegner et al. 2005). Furthermore, collisions between
replication and transcription complexes cause instability at
fragile sites in the longest human genes (Helmrich et al.
2011). In the case of Chaos3 cancers, there may be a pre-
disposition for replication fork stalling at particular genomic
regions that are problematic for the destabilized Chaos3
helicase (Chuang et al. 2012), coupled with selective growth
advantage conferred to cells by such mutations. Another cu-
rious issue has to do with strain specificity of Chaos3 mam-
mary tumors, which occur on the C3H but not C57BL/6J
background. One possible explanation may be related to
differential DNA replication mechanics per se. Chaos3 cells
have reduced Mcm2-7 mRNA and protein levels that lead
to a decreased number of backup (“dormant”) replication
origins (Kawabata et al. 2011a; Chuang et al. 2012), and
these two strains differ in the density of licensed origins
(Kawabata et al. 2011b). Backup origins are important for
rescue of stalled or collapsed DNA replication forks that
may otherwise lead to chromosomal aberrations (Blow et al.
2011). The Nf1 region may be particularly susceptible to
stalled replication forks, and thus strain differences in
backup origin density could have an impact. Alternatively,
the two strains may have differential chromatin structure
near Nf1 and/or other key tumor drivers in mammary epi-
thelial cells, leading to an increased likelihood of CNAs in
those regions. Finally, there may be genetic differences be-
tween the strains that confer biological resistance or suscep-
tibility of an unknown nature. These differences would be
mappable by standard genetic crosses, lending insight into
heritable factors in breast cancer.
Figure 4 Nf1 deletion in Chaos3 mammary tumors leads to increased activated RAS and sensitivity to PI3K and MAPK inhibitors. (A) Western blot
analysis of Chaos3 tumors for NF1 and active RAS levels. The mammary tumors without detectable NF1 have homozygous deletions of Nf1 (Table S4),
whereas the bone tumor and mammary tumor 22418 contain no Nf1 deletions. The presence of NF1 protein is inversely correlated with the level
of activated (GTP-bound RAS). (B) NF1 and the Ras pathway. NF1 loss leads to increased cell proliferation and transcription of antiapoptosis genes
because of failure to negatively regulate Ras. Inhibitors used in this study to slow proliferation of NF1-deficient tumor cells are shown in red type. Not
all downstream targets are shown. RTK, receptor tyrosine kinase. (C) Cell proliferation assays showing sensitivity of Chaos3 tumors to rapamycin and
Mek1 inhibitor PD98059. Line colors: red, HeLa; brown, MCF-7 and MDA-MB231; blue, PyVT; and black, Chaos3. BT, bone tumor; MT, mammary
tumor; MTCL, mammary tumor cell line.
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The C3H-Chaos3mouse has important features that make
it a highly relevant breast cancer model. First, because it is
not genetically engineered to lack a tumor suppressor or
express an oncogene, the cancers are driven by spontaneous
events. Presumably, these events are mutations arising as
a secondary consequence of the Mcm4Chaos3 genomic insta-
bility allele. Second, tumor differentiation score analyses of
mRNA levels indicated that Chaos3 mammary tumors more
closely resemble human luminal precursors than all other
characterized mouse models. Finally, the secondary muta-
tions arising in this model are primarily interstitial CNAs
that are limited in number, relatively small in size, and often
have nested breakpoints that refine the “critical regions”
containing potential cancer driver genes. Together, the mouse
and TCGA human data indicate that NF1 loss in conjunction
with other CNAs is important for initiation and maintenance
of mammary tumorigenesis in Chaos3 mice and a substantial
subset of human patients. Among the other CNAs, Ube4b and
Kif1b were frequently deleted in Chaos3 mammary tumors
specifically, and human breast tumors also show frequent
deletion (26%; Table 3, Table S2, and Figure S3). Genes
in these and other recurrently altered regions are candidates
for future studies of potential susceptibility genes underly-
ing spontaneous or heritable forms of breast cancer.
Identification of NF1 as a potential tumor driver in a sub-
set of breast cancers can provide guidance for patient treat-
ment. First, suppression of the RAS pathway would be an
appropriate target. However, loss or decrease of NF1 may
trigger more than RAS pathway activation, as NF1 has been
shown to bind to focal adhesion kinase (FAK) and has mul-
tiple isoforms of unknown functions (Kweh et al. 2009).
Second, there is reason to believe that tamoxifen, the estro-
gen receptor (ER) inhibitor that is standard treatment for
ER+ breast cancers, may not be appropriate for women
whose cancers involve NF1 mutations. NF1 depletion was
reported to confer resistance of human breast cancer (MCF7)
cells to tamoxifen, and tamoxifen-treated patients whose
tumors had lower NF1 expression levels had poorer clinical
outcomes (Mendes-Pereira et al. 2012).
Based on cancer incidence estimates (Jemal et al. 2011;
Siegel et al. 2012) and the frequency of NF1 deletions
(Figure 5A), 63,450 patients in the United States and
383,230 worldwide will develop breast cancer with an NF1
deficiency annually. Our results demonstrate a consistent
pattern of spontaneous CNAs associated with mouse and
human mammary tumor carcinogenesis, particularly the im-
portance of Nf1 deletion and provide a model for validation
of these genes and drugs that target them.
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Figure 5 Frequent NF1 deletion in human breast cancer. (A) Percentage of NF1 CNA and mutation in 511 human breast tumors, including 57 Her2-
Enriched and 93 Basal breast tumors (publically available TCGA data). Note that 27.7% of human breast tumors have NF1 deletion or mutation, and
HER2-enriched and basal breast tumor subtypes have $40% NF1 deletion or mutation. (B) Boxplot of NF1 mRNA expression vs. copy number in human
breast cancer. Data are from TCGA Research Network. P-value is for ANOVA between het-loss and diploid groups, indicating expression levels
significantly correlate with genomic deletion status.
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Figure	  S1	  	  	  Chaos3	  tumors	  demonstrate	  high	  levels	  of	  GIN	  and	  aneuploidy.	  	  (A)	  Metaphase	  spreads	  from	  cells	  of	  3	  Chaos3	  mammary	  tumors.	  	  Note	  
aneuploidy	  in	  left	  and	  middle	  spreads	  compared	  to	  the	  normal	  40	  chromosomes	  (left	  to	  right:	  414,	  83,	  40).	  	  (B)	  Examination	  of	  16	  Chaos3	  tumors	  
reveal	  a	  normal	  chromosome	  count	  in	  an	  average	  of	  only	  1/3	  of	  the	  cells	  (>Tetra=	  Beyond	  Tetraploidy;	  Tetra=Tetraploid;	  Amp=Amplification;	  
Del=Deletion).	  	  (C)	  Metaphase	  spreads	  from	  one	  Chaos3	  mammary	  tumor	  (16864a).	  	  Chromosome	  count	  is	  indicated	  beneath	  the	  images.	  	  Note	  the	  
extreme	  variation	  of	  aneuploidy	  found	  within	  a	  single	  tumor.	  	  (D)	  Additional	  abnormal	  features	  displayed	  by	  tumor	  cells,	  including:	  cruciform	  
structures	  (left)	  and	  abnormal	  multi-­‐nucleated	  cells	  (middle	  and	  right).	  	  
	   	  













































Figure	  S2	  	  	  Genomic	  sequence	  around	  Nf1	  is	  prone	  to	  CNA	  and	  contains	  a	  genomic	  rearrangement.	  	  Colored	  vertical	  bars	  represent	  the	  deleted	  
region	  in	  7	  Chaos3	  mammary	  tumors	  as	  detected	  by	  aCGH,	  and	  the	  percentages	  reflect	  how	  many	  of	  these	  tumors	  contain	  CNA	  for	  a	  given	  mouse	  
gene.	  	  Gene	  names	  in	  red	  denote	  the	  Chaos3	  critical	  region.	  	  Mouse	  and	  human	  genomic	  orientations	  of	  the	  Nf1	  region	  are	  depicted.	  	  TRUE/FALSE	  
indicates	  TCGA	  Level	  4	  (limited	  dataset)	  analysis	  of	  a	  subset	  of	  invasive	  breast	  carcinomas	  for	  segmental	  CNAs;	  it	  is	  possible	  that	  the	  intervals	  
between	  NOS2	  and	  NF1	  are	  actually	  part	  of	  more	  inclusive	  deletion	  events.	  	  Numbers	  in	  bold	  with	  small	  arrows	  indicate	  positions	  of	  interest:	  	  1.	  
Proximal	  to	  Nf1,	  a	  breakpoint	  of	  chromosomal	  inversion	  between	  human	  and	  mouse	  occurred	  between	  and	  including	  Wsb1	  to	  Aldoc.	  	  This	  is	  a	  site	  
of	  both	  human	  and	  mouse	  tumor	  CNA,	  and	  the	  human	  CNA	  begins	  with	  NF1.	  	  2.	  The	  mouse	  critical	  CNA	  begins	  at	  Ksr1,	  which	  has	  flipped	  
orientation	  in	  humans	  and	  starts/forms	  a	  second	  smaller	  CNA,	  with	  the	  caveats	  mentioned	  above.	  	  3.	  The	  mouse	  genome	  has	  an	  insertion	  between	  
Nlk	  and	  Nos2,	  where	  human	  statistically-­‐declared	  CNAs	  end.	  	  
	   	  












































Figure	  S3	  	  	  Ube4b	  and	  Kif1b,	  deleted	  in	  over	  half	  of	  Chaos3	  mammary	  tumors,	  show	  frequent	  deletion	  in	  human	  breast	  tumors.	  	  (A)	  Recurrent	  Chr	  4	  
deletions	  specific	  to	  mammary	  tumors	  (MT).	  Horizontal	  bars	  represent	  tumors	  examined	  by	  aCGH.	  Red	  portions	  of	  bars	  indicate	  deleted	  regions	  in	  
Chaos3	  and	  MMTV-­‐neu	  MTs.	  	  Cancer-­‐related	  genes	  are	  in	  red.	  	  Note	  that	  Chaos3	  non-­‐MTs	  do	  not	  demonstrate	  this	  deletion.	  BT=bone	  tumor;	  
LYMPH	  =	  Lymphoma;	  HSTSC=histiocytic	  sarcoma.	  (B)	  “Oncoprints”	  of	  Ube4b	  and	  Kif1b	  alterations	  in	  320	  human	  breast	  tumors	  (TCGA	  data)	  
generated	  by	  the	  cBio	  portal	  (see	  Methods).	  	  Rows	  contain	  bars	  representing	  individual	  tumors,	  and	  samples	  are	  aligned	  for	  visualization	  of	  
alterations	  within	  the	  same	  tumor	  across	  multiple	  genes.	  	  Hmx1	  does	  not	  have	  a	  known	  role	  in	  cancer.	  	  (C)	  Percentage	  of	  Ube4b	  and	  Kif1b	  CNAs	  in	  
55	  Her2-­‐Enriched,	  125	  Luminal	  B,	  and	  93	  Basal	  human	  breast	  tumors	  (TCGA).	  	  Note	  that	  ~40%	  of	  HER2-­‐Enriched	  and	  Luminal	  B	  tumors	  have	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Table	  S1	  	  	  Validated	  Gene	  Mutations	  in	  Chaos3	  Mammary	  Tumors	  
Sample	   Name	   Mutation	   Effect	   Description	   Function	  
15259	   Myo1g	   G/A	   Splice	  Site	   Myosin-­‐Ig	  	  	   Precursor	  of	  minor	  histocompatibility	  antigen	  HA-­‐2	  
2042	   Acsl6	   G/T	   E>D	   Long-­‐chain-­‐fatty-­‐
acid-­‐-­‐CoA	  ligase	  6	  	  
Catalyze	  formation	  of	  acyl-­‐CoA	  from	  fatty	  acids,	  ATP,	  and	  CoA.	  	  
2042	   Tdrd6	   T/C	   H>R	   Tudor	  domain-­‐
containing	  protein	  
6	  	  
Required	  for	  spermiogenesis,	  chromatoid	  body	  architecture,	  and	  
regulation	  of	  miRNA	  expression.	  
2042	   Ttn	   C/T	   D>N	   Titin	  (Connectin)	  	   Cardiac	  and	  skeletal	  muscle	  protein.	  Disease	  Associations:	  
Familial	  Cardiomyopathy,	  Tibial	  muscular	  dystrophy	  
2044b	   Ttn	   C/G	   V>L	   Titin	  (Connectin)	  	   	  	  
	  
Note:	  The	  mutations	  were	  validated	  by	  Sanger	  sequencing	  of	  PCR	  products.	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Table	  S2	  	  	  Chaos3	  -­‐specific	  and	  Mammary	  Tumor-­‐specific	  Recurrent	  Deletions	  Overlapping	  Human	  Breast	  Cancer	  CNAs.	  
	  
	   	   	   Tumors	  
Mouse	  CNA	  	   Gene	  
Hum	  
Chr	   Human	  CNA	  	  
Chaos3	  
CNA	  	   A	   B	   C	   D	   E	   F	   G	   H	   I	  
Mmu	  Chr	  4	  	   SLC2A7	   1	   FALSE	   33%	   	   x	  
	   	  
x	  
	   	   	  
	  
148.4-­‐149.5	  Mb	   SLC2A5	   1	   FALSE	   50%	   	   x	  
	   	  
x	   x	  
	   	  
	  
	  
GPR157	   1	   FALSE	   50%	   	   x	  
	   	  
x	   x	  
	   	  
	  
	  
MIR34A	   1	   FALSE	   50%	   	   x	  
	   	  
x	   x	  
	   	  
	  
	  
H6PD	   1	   FALSE	   57%	   	   x	  
	   	  




SPSB1	   1	   FALSE	   86%	   	   x	   x	   	  	   x	   x	   x	   x	   	  
	  
SLC25A33	   1	   FALSE	   86%	   	   x	   x	   	  	   x	   x	   x	   x	   	  
	  
TMEM201	   1	   FALSE	   86%	   	   x	   x	   	  	   x	   x	   x	   x	   	  
	  
PIK3CD	   1	   FALSE	   86%	   	   x	   	  	   x	   x	   x	   x	   x	   	  
	  
CLSTN1	   1	   FALSE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
CTNNBIP1	   1	   FALSE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
LZIC	   1	   FALSE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
NMNAT1	   1	   FALSE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
RBP7	   1	   FALSE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
UBE4B	   1	   TRUE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
KIF1B	   1	   TRUE	   71%	   	   x	   	  	   x	   x	   	  	   x	   x	   	  
	  
PGD	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	  
x	   	  
	  
APITD1	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	  
x	   	  
	  
CORT	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	  
x	   	  
	  
DFFA	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	  
x	   	  
	  
PEX14	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	  
x	   	  
	  
CASZ1	   1	   TRUE	   33%	   	   x	  
	  
x	  
	   	   	   	  
	  
	  
TARDBP	   1	   FALSE	   17%	   	   x	  
	   	   	   	   	   	  
	  
	  
MASP2	   1	   FALSE	   17%	   	   x	  
	   	   	   	   	   	  
	  
	  
SRM	   1	   FALSE	   17%	   	   x	  
	   	   	   	   	   	  
	  
Mmu	  Chr	  5	  	   CLIP1	   12	   FALSE	   43%	   x	   x	   	  
	   	  
	   x	  
	  
	  
122-­‐125	  Mb	   ZCCHC8	   12	   FALSE	   43%	   x	   x	   	  
	   	  




RSRC2	   12	   FALSE	   43%	   x	   x	   	  
	   	  
























VPS37B	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
ABCB9	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
OGFOD2	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
ARL6IP4	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
PITPNM2	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
MPHOSPH9	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
CDK2AP1	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
SBNO1	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	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SETD8	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
RILPL2	   12	   FALSE	   86%	   x	   x	   x	   x	   	   	   x	   	  	   x	  
	  
SNRNP35	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
RILPL1	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
TMED2	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
DDX55	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
EIF2B1	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
GTF2H3	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
TCTN2	   12	   FALSE	   100%	   x	   x	   x	   x	   	   	   x	   x	   x	  
	  
ATP6V0A2	   12	   FALSE	   43%	   	  
	   	   	   	  
x	  
	  
x	   x	  
	  
CCDC92	   12	   FALSE	   29%	   	  
	   	   	   	   	   	  
x	   x	  
	  
Zfp664	   12	   FALSE	   14%	   	  
	   	   	   	   	   	  
x	   	  
	  
Fam101a	   12	   TRUE	   14%	   	  
	   	   	   	   	   	  
x	   	  
	  
Ncor2	   12	   TRUE	   14%	   	  
	   	   	   	   	   	  
x	   	  
	  
Scarb1	   12	   FALSE	   14%	   	   	  	   	  	   	  	   	  	   	  	  
	  
x	   	  
Mmu	  Chr	  11	   WSB1	   17	   FALSE	   100%	   x	   x	   x	   *	   x	   *	   x	   x	   x*	  
	  78-­‐79.6	  Mb	   KSR1	   17	   TRUE	   100%	   x	   x	   x	   *	   x	   *	   x	   x	   x*	  
	  






x	   x*	  
	  






x	   	  
	  






x	   	  
	  






x	   	  
	  






x	   	  
	  






x	   	  
	  
POLDIP2	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
TMEM199	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
SEBOX	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
VTN	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
SARM1	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
SLC46A1	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
SLC13A2	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
FOXN1	   17	   FALSE	   29%	   	   x	  
	  
	  
	   	   	  
x	   	  
	  
UNC119	   17	   FALSE	   17%	   	   x	  
	  
	  
	   	   	   	  
	  
	  
PIGS	   17	   FALSE	   17%	   	   x	  
	  
	  
	   	   	   	  
	  
	  
ALDOC	   17	   FALSE	   17%	   	   x	  
	  
	  
	   	   	   	  
	  
	  
NF1	   17	   TRUE	   100%	   x	   x	   x	   x*	   x	   x*	   x	   x	   x	  
	  
OMG	   17	   TRUE	   86%	   x	   x	   x	   x*	   x	  
	  
x	   	  	   x	  
	  
EVI2B	   17	   TRUE	   86%	   x	   x	   x	   *	   x	  
	  
x	   	  	   x	  
	  





	  	   RAB11FIP4	   17	   TRUE	   57%	   x	   x	   x	   x*	   x	   	  	   	  	   	  	   	  
Legend.	  	  x=	  deleted	  as	  determined	  by	  aCGH	  analysis.	  Some	  qPCR	  genotyping	  from	  the	  Chr	  11	  interval	  was	  added,	  and	  deleted	  probes	  are	  indicated	  
as	  x*.	  	  Presumed	  deleted	  probes	  are	  indicated	  by	  “*”.	  	  Tumor	  Codes:	  A:	  2044B;	  B:	  12353A;	  C:	  12351L;	  D:	  12352;	  E:	  15259;	  F:	  16168;	  G:	  12115B;	  H:	  
16898;	  I:	  11929A.	  	  Mmu	  =	  Mus	  musculus.	  Some	  of	  the	  deletions	  extend	  further	  than	  indicated.	  The	  True	  (deleted)	  and	  False	  (not	  deleted)	  calls	  for	  
human	  gene	  deletions	  are	  from	  TCGA	  level	  4	  data	  (see	  Methods)	  and	  refer	  to	  whether	  that	  locus	  is	  deleted	  at	  levels	  statistically	  above	  background.	  
Human	  genes	  in	  red	  are	  potentially	  cancer-­‐relevant	  if	  deleted.	  Red	  shaded	  regions	  are	  the	  “critical	  regions”	  of	  a	  deletion	  set.	  Note	  that	  the	  Mmu	  
Chr	  11	  deletion	  cluster	  is	  organized	  in	  the	  human	  genome	  order,	  which	  is	  inverted	  and	  has	  an	  insertion.	  Thus,	  the	  critical	  region	  is	  actually	  
contiguous.	  The	  “Chaos3	  CNA”	  column	  refers	  to	  the	  %	  of	  Chaos3	  mammary	  tumors	  analyzed	  by	  aCGH	  that	  contained	  deletions	  of	  that	  particular	  
locus.	  ND=no	  data.	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Table	  S3	  	  	  Chaos3	  Mammary	  Tumor	  Non-­‐specific	  Recurrent	  Deletions	  Overlapping	  Human	  Breast	  Cancer	  CNAs.	  
	  
Mouse	  Region	  	   Human	  Gene	  
Hs	  
Chr	   Human	  CNA	  	  
Chaos3	  
CNA	  	   A	   B	   C	   D	   E	   F	   G	  
Mmu	  Chr	  4	  	   AIM1L	   1	   FALSE	   43%	  
	  
x	   x	  
	   	  
x	  
	  132.4-­‐133.5	  Mb	   LIN28	   1	   FALSE	   71%	  
	  
x	   x	   x	  
	  
x	   x	  
	  	   DHDDS	   1	   FALSE	   71%	  
	  
x	   x	   x	  
	  
x	   x	  
	  	   HMGN2	   1	   FALSE	   71%	  
	  
x	   x	   x	  
	  
x	   x	  
	  	   RPS6KA1	   1	   FALSE	   86%	   	  	   x	   x	   x	   x	   x	   x	  
	  	   ARID1A	   1	   FALSE	   100%	   x	   x	   x	   x	   x	   x	   x	  
	  	   PIGV	   1	   FALSE	   100%	   x	   x	   x	   x	   x	   x	   x	  
	  	   ZDHHC18	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   SFN	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   GPN2	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   GPATCH3	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   NR0B2	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   NUDC	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   TRNP1	   1	   TRUE	   86%	   x	   x	   x	   	  	   x	   x	   x	  
	  	   FAM46B	   1	   FALSE	   86%	   x	   x	   x	   	  	   x	   x	   x	  




x	   x	   x	  
	  	   WDTC1	   1	   FALSE	   43%	   x	  




	  	   TMEM222	   1	   FALSE	   43%	   x	  




	  	   SYTL1	   1	   FALSE	   43%	   x	  




	  	   MAP3K6	   1	   FALSE	   43%	   x	  




	  	   CD164L2	   1	   FALSE	   43%	   x	  




	  	   GPR3	   1	   FALSE	   43%	   x	   	  	   	  	   	  	   x	   	  	   x	  
Mmu	  Chr	  10	   PPAP2C	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  79.4-­‐80.2	  Mb	   MIER2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   THEG	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   C2CD4C	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   SHC2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   ODF3L2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   MADCAM1	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   CDC34	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   GZMM	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   BSG	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   HCN2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   POLRMT	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   FGF22	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   RNF126	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   FSTL3	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   PRSSL1	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   PALM	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   PTBP1	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   PRTN3	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   ELANE	   19	   TRUE	   33%	  
	   	   	  
x	   x	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   CFD	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   MED16	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   KISS1R	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   ARID3A	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   WDR18	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   GRIN3B	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   CNN2	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   ABCA7	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   HMHA1	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   POLR2E	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   GPX4	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   SBNO2	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   STK11	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   ATP5D	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   MIDN	   19	   TRUE	   50%	  
	   	   	  
x	   x	  
	  
x	  
	  	   CIRBP	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   EFNA2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   MUM1	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   NDUFS7	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   GAMT	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   DAZAP1	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   RPS15	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   APC2	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   PCSK4	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   REEP6	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   ADAMTSL5	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   MEX3D	   19	   TRUE	   50%	  
	   	   	  
x	   x	   x	  
	  	  	   MBD3	   19	   TRUE	   50%	  
	   	   	  
x	   x	   x	  
	  	  	   TCF3	   19	   TRUE	   50%	  
	   	   	  
x	   x	   x	  
	  	  	   ONECUT3	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   ATP8B3	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   REXO1	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   KLF16	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   SCAMP4	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   ADAT3	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   CSNK1G2	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   BTBD2	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   MKNK2	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   MOBKL2A	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   AP3D1	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   DOT1L	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   PLEKHJ1	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   SF3A2	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   AMH	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   JSRP1	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   OAZ1	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	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   LINGO3	   19	   TRUE	   67%	   x	   	  	   	  	   x	   x	   x	   	  	  
	  	   LSM7	   19	   TRUE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   TMPRSS9	   19	   FALSE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   TIMM13	   19	   FALSE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   LMNB2	   19	   FALSE	   33%	  
	   	   	  
x	   x	  
	   	  	  	   GADD45B	   19	   FALSE	   17%	   	  	   	  	   	  	   x	   	  	   	  	   	  	  
Legend.	  	  x=	  deleted.	  Tumor	  Codes:	  A:	  15259;	  B:	  12353A;	  C:	  12115B;	  D:	  11929A;	  E:	  16898;	  F:	  2044B;	  G:	  16892.	  Mmu	  =	  Mus	  musculus.	  Hs	  =	  Homo	  
sapiens.	  Some	  of	  the	  deletions	  extend	  further	  than	  indicated.	  The	  True	  (deleted)	  and	  False	  (not	  deleted)	  calls	  for	  human	  gene	  deletions	  are	  from	  
TCGA	  level	  4	  data	  (see	  Methods)	  and	  refer	  to	  whether	  that	  locus	  is	  deleted	  at	  levels	  statistically	  above	  background.	  Human	  genes	  in	  red	  are	  
potentially	  cancer-­‐relevant.	  Red	  shaded	  regions	  are	  the	  “critical	  regions”	  of	  a	  deletion	  set.	  The	  “Chaos3	  CNA”	  column	  refers	  to	  the	  %	  of	  Chaos3	  
mammary	  tumors	  analyzed	  by	  aCGH	  that	  contained	  deletions	  of	  that	  particular	  locus.	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Table	  S4	  	  	  	  qPCR	  analysis	  of	  Nf1	  locus	  in	  tumors	  
	  
	  
Geno	  &	  Type	   Tumor	  #	   Nf1	  5'	   Nf1	  3'	  (Omg)	  
	  
	  	   	  	   	  	  
Chaos3	  MT	   15259	   17.4	   52.9	  
Chaos3	  MT	   12351	  L	   35.5	   12.0	  
Chaos3	  MT	   12353A	   25.5	   16.7	  
Chaos3	  MT	   12352	   12.7	   0.7	  
Chaos3	  MT	   2044B	  CL	   63.7	   48.0	  
Chaos3	  MT	   11929A	   16.7	   16.3	  
Chaos3	  MT	   16168	   9.2	   ND	  
Chaos3	  MT	   16898	   9.6	   75.1	  
Chaos3	  MT	   12115B	   31.2	   38.7	  
Chaos3	  MT	   2042	  CL	   78.9	   92.3	  
Chaos3	  MT	   919	  CL	   51.8	   0.1	  
Chaos3	  MT	   21040	   0.1	   0.1	  
Chaos3	  MT	   21253	   0.3	   0.2	  
Chaos3	  MT	   20317	   29.5	   48.7	  
Chaos3	  MT	   19957	   32.7	   5.4	  
Chaos3	  MT	   19958	   11.2	   12.4	  
Chaos3	  MT	   19959	   14.4	   72.4	  
Chaos3	  MT	   20783	   7.0	   10.4	  
Chaos3	  MT	   20164	   20.6	   22.8	  
Chaos3	  MT	   20888	   27.3	   26.0	  
Chaos3	  MT	   20892	   6.4	   34.9	  
Chaos3	  MT	   20893	   7.4	   24.5	  
Chaos3	  MT	   20138	   41.1	   10.8	  
Chaos3	  MT	   21039	   68.4	   66.7	  
Chaos3	  MT	   21809	   62.0	   60.0	  
Chaos3	  MT	   20894	   85.1	   67.1	  
Chaos3	  MT	   20889	   12.0	   18.4	  
Chaos3	  MT	   21333	   40.8	   71.4	  
Chaos3	  MT	   20626	   36.7	   22.6	  
Chaos3	  MT	   20318	   14.5	   24.9	  
Chaos3	  MT	   20890	   13.6	   38.9	  
Chaos3	  MT	   20891	   2.5	   1.4	  
Chaos3	  MT	   21123	   34.7	   39.0	  
Chaos3	  MT	   19660	   44.8	   48.3	  
Chaos3	  MT	   20459	   53.7	   69.8	  
Chaos3	  MT	   21597	   28.6	   5.3	  
Chaos3	  MT	   22182	   62.6	   78.2	  
Chaos3	  MT	   21416	   63.8	   56.8	  
Chaos3	  MT	   22236	   31.6	   8.0	  
Chaos3	  MT	   22418	   24.9	   24.2	  
Chaos3	  MT	   22180	   23.9	   49.0	  
Chaos3	  MT	   22235	   8.1	   8.2	  
Chaos3	  MT	   22166	   21.7	   21.0	  
Chaos3	  MT	   22168	   8.0	   7.6	  
Chaos3	  MT	   22238	   3.4	   3.4	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Chaos3	  MT	   21417	   3.3	   14.8	  
Chaos3	  MT	   21419	   19.2	   50.6	  
Chaos3	  MT	   21255	   7.0	   6.1	  
Chaos3	  MT	   21124	   8.5	   29.1	  
Chaos3	  MT	   21810	   26.3	   27.0	  
Chaos3	  MT	   21811	   47.3	   51.7	  
Chaos3	  MT	   21254	   9.5	   7.9	  
Chaos3	  MT	   21041	   24.4	   21.2	  
Chaos3	  MT	   22420	   40.5	   17.1	  
Chaos3	  MT	   22476	   75.5	   70.7	  
Chaos3	  MT	   22414	   3.3	   17.1	  
Chaos3	  MT	   22416	   3.5	   14.6	  
Chaos3	  MT	   22417	   7.1	   19.4	  
Chaos3	  MT	   23116	   11.2	   10.8	  
Chaos3	  MT	   22418	   115.0	   110.3	  
Chaos3	  non-­‐MT	   19160	   198.2	   207.5	  
Chaos3	  non-­‐MT	   10658	   87.1	   ND	  
Chaos3	  non-­‐MT	   16862	   98.5	   101.2	  
Chaos3	  non-­‐MT	   17883	   97.0	   88.0	  
PyVT	  
	  
96.3	   105.1	  
MMTV-­‐neu1	  
	  
108.6	   93.2	  
MMTV-­‐neu2	  
	  
103.8	   104.4	  
Chaos3	  +/+	  MT	  
	  
107.3	   109.4	  
	  
Legend.	  qPCR	  values	  are	  presented	  as	  the	  percentage	  vs	  C3H	  DNA.	  	  Nf1	  probes	  were	  at	  the	  5'	  and	  3'	  ends	  of	  the	  gene.	  The	  3’	  probe	  actually	  
corresponds	  to	  the	  Omg	  gene	  that	  lies	  within	  an	  Nf1	  intron	  near	  the	  3'	  end.	  	  Note	  that	  copy	  number	  differences	  between	  the	  Nf1	  5'	  and	  3'	  are	  
observed	  in	  some	  tumors,	  indicating	  a	  breakpoint	  within	  Nf1.	  	  Deletion	  calls	  were	  made	  as	  follows:	  Heterozygous	  =	  15-­‐80%;	  Homozygous	  =	  <15%.	  If	  
either	  Nf1	  or	  Omg	  were	  <15%,	  the	  tumor	  sample	  was	  called	  as	  homozygous	  deleted	  because	  full	  Nf1	  transcripts	  cannot	  be	  made.	  MT	  =	  mammary	  
tumor.	  
	  
	  
	  
	  
